Big Pharma’s business-as-usual playbook relies on egregious pricing practices and rhetoric designed to set and keep drug prices high.

Drug prices in the United States are out of control as a direct result of the egregious pricing and anti-competitive practices of brand name pharmaceutical companies. Rising prescription drug prices threaten the affordability of our health care system, the long-term health of our nation and the vitality of our entire economy. Public opinion research finds as many as one-in-three Americans experience financial difficulty, either as a patient themselves or through a family member, affording prescription drugs. CSRxP has developed market-based solutions to restore a functioning market and lower prices for patients by increasing list price transparency, promoting competition and actual innovation and focusing on better value for patients, not better value for pharmaceutical companies.

Oct 21, 2026

DOSE OF REALITY: NEW ICER REPORT FINDS BIG PHARMA’S LAUNCH PRICES REMAIN OUT OF CONTROL AND UNJUSTIFIED BY CLINICAL VALUE

Median Net Launch Prices Have Increased 35 Percent Since 2022, With Nearly One in Four…

Oct 14, 2026

THEY SAID IT! R STREET CALLS FOR BIPARTISAN, MARKET-BASED SOLUTIONS TO CRACK DOWN ON BIG PHARMA’S PATENT ABUSE

Article Highlights How Congress Can Address Patent Thickets, Product Hopping And Other…

Oct 14, 2026

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Big Pharma Giant Beats Earnings, Projects $100 Billion in Annual Sales Following Price…

Sep 30, 2026

DOSE OF REALITY: JAMA STUDY FINDS DRUG PATENT PORTFOLIOS ON SMALL MOLECULE DRUGS HAVE MORE THAN TRIPLED, DELAYING GENERIC COMPETITION

New Analysis Shows Brand Name Drug Companies Increasingly Rely On Follow-On Patents To…

Oct 21, 2026

DOSE OF REALITY: NEW ICER REPORT FINDS BIG PHARMA’S LAUNCH PRICES REMAIN OUT OF CONTROL AND UNJUSTIFIED BY CLINICAL VALUE

Median Net Launch Prices Have Increased 35 Percent Since 2022, With Nearly One in Four…

Oct 14, 2026

THEY SAID IT! R STREET CALLS FOR BIPARTISAN, MARKET-BASED SOLUTIONS TO CRACK DOWN ON BIG PHARMA’S PATENT ABUSE

Article Highlights How Congress Can Address Patent Thickets, Product Hopping And Other…

Oct 14, 2026

BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON

Big Pharma Giant Beats Earnings, Projects $100 Billion in Annual Sales Following Price…

Sep 30, 2026

DOSE OF REALITY: JAMA STUDY FINDS DRUG PATENT PORTFOLIOS ON SMALL MOLECULE DRUGS HAVE MORE THAN TRIPLED, DELAYING GENERIC COMPETITION

New Analysis Shows Brand Name Drug Companies Increasingly Rely On Follow-On Patents To…

Videos

Watch and learn about Big Pharma’s price-gouging techniques that are the cause of out-of-control drug prices.

Fact Sheets

Get the facts on Big Pharma’s anti-competitive tactics, like price-gouging and patent abuse that keeps drug prices high.

Infographics

Learn about how Big Pharma is driving the Rx drug pricing crisis with our infographics.

Polling

See recent surveys on American voters’ opinions on Big Pharma’s blame game and out-of-control drug pricing.

Join us in telling lawmakers: It’s time to hold Big Pharma accountable and lower Rx drug prices.

This field is for validation purposes and should be left unchanged.
By signing your name, you are opting-in to receive calls and SMS/MMS messages, including autodialed and automated calls and texts, to that number from CSRxP. Msg & data rates may apply.